Article
Oncology
Alexander Muik, Homer C. Adams, Friederike Gieseke, Isil Altintas, Kristina B. Schoedel, Jordan M. Blum, Bianca Sanger, Saskia M. Burm, Eliana Stanganello, Dennis Verzijl, Vanessa M. Spires, Fulvia Vascotto, Aras Toker, Juliane Quinkhardt, Mark Fereshteh, Mustafa Diken, David P. E. Satijn, Sebastian Kreiter, Tahamtan Ahmadi, Esther C. W. Breij, Ozlem Tureci, Kate Sasser, Ugur Sahin, Maria Jure-Kunkel
Summary: DuoBody-CD40x4-1BB is a novel antibody capable of enhancing antitumor immunity by modulating the functions of immune cells. In vitro and in vivo experiments have demonstrated its ability to enhance dendritic cell and T-cell functions, as well as its biological activity in patients with advanced solid tumors. These findings suggest that targeting CD40 and 4-1BB with an Fc-inert bispecific antibody may be an effective approach for cancer treatment.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Cell Biology
Tetje C. van der Sluis, Guillaume Beyrend, Esme T. I. van der Gracht, Tamim Abdelaal, Simon P. Jochems, Robert A. Belderbos, Thomas H. Wesselink, Suzanne van Duikeren, Floortje J. van Haften, Anke Redeker, Laura F. Ouboter, Elham Beyranvand Nejad, Marcel Camps, Kees L. M. C. Franken, Margot M. Linssen, Peter Hohenstein, Noel F. C. C. de Miranda, Hailiang Mei, Adriaan D. Bins, John B. A. G. Haanen, Joachim G. Aerts, Ferry Ossendorp, Ramon Arens
Summary: Immune checkpoint therapy (ICT) has the potential to eliminate cancer, but the underlying mechanisms determining its effectiveness are not fully understood. By using high-dimensional single-cell profiling, this study investigates if the T cell landscape in peripheral blood can predict responses to combinatorial targeting of the OX40 costimulatory and PD-1 inhibitory pathways. The findings reveal dynamic activation states of therapy-responsive T cells and emphasize the importance of NK cell receptors and chemokine receptors in therapy-induced anti-tumor immunity.
CELL REPORTS MEDICINE
(2023)
Article
Oncology
Gi-Hoon Nam, Minsu Kwon, Hanul Jung, Eunbyeol Ko, Seong A. Kim, Yoonjeong Choi, Su Jeong Song, Seohyun Kim, Yeji Lee, Gi Beom Kim, Jihoon Han, Jiwan Woo, Yakdol Cho, Cherlhyun Jeong, Seung-Yoon Park, Thomas M. Roberts, Yong Beom Cho, In-San Kim
Summary: The study shows that statins can enhance the immunogenicity of KRAS-mutant tumors by inducing immunogenic cell death and enhancing the cross-priming ability of dendritic cells, thereby stimulating CD8+ T-cell immune responses against the tumors. Combination therapy using statins and other agents can significantly increase the immunogenicity of KRAS(mut) tumors and improve tumor-specific immunity, overcoming resistance to PD-1 blockade therapies and increasing survival rates in KRAS(mut) tumor models.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Veterinary Sciences
Jae-Yeon Park, Jihoon Ryu, Jung-Eun Park, Eui-Ju Hong, Hyun-Jin Shin
Summary: This study found that HSP70 plays an important role in PEDV replication, with its overexpression increasing the speed of viral replication, while knockout significantly reduces PEDV protein expression and replication. Furthermore, the study confirmed the crucial role of the PEDV membrane (M) protein in collaboration with HSP70 in viral replication in infected cells.
VETERINARY RESEARCH
(2021)
Article
Immunology
Adele Friot, Sophia Djebali, Severine Valsesia, Peggy Parroche, Maxence Dubois, Jessica Baude, Francois Vandenesch, Jacqueline Marvel, Yann Leverrier
Summary: Staphylococcus aureus is a pathogen associated with various diseases and the emergence of antibiotic-resistant strains has raised concerns. Developing vaccines may help overcome these resistant strains, but the ability of S. aureus to internalize into cells poses a challenge. This study explores the potential of CD8(+) T cells to recognize and kill S. aureus-infected dendritic cells, paving the way for CD8(+) T cell-based therapies against S. aureus.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY
(2023)
Review
Oncology
Kedar Kirtane, Hany Elmariah, Christine H. Chung, Daniel Abate-Daga
Summary: Immune checkpoint inhibitors have significantly changed the standard care for many solid tumor malignancies, but resistance remains common. Adoptive cellular therapy is a rapidly growing form of immunotherapy that shows promise in overcoming resistance mechanisms and has already revolutionized the treatment of hematologic malignancies. The use of ACT in solid tumor malignancies is still in its early stages, with promising therapies under active investigation.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2021)
Article
Immunology
Jie Qian, Xiaofei Yu, Zheng Liu, Jinyang Cai, Masoud H. Manjili, Hu Yang, Chunqing Guo, Xiang-Yang Wang
Summary: In this study, we found that inhibiting the activity of scavenger receptor A (SRA) can enhance the immunogenicity of dendritic cells (DCs) in capturing chaperone vaccines targeting melanoma and breast cancer. The downregulation of SRA leads to increased activation of antigen-specific T cells and inhibition of tumor growth. Additionally, we discovered that the administration of a chitosan-siRNA complex can effectively reduce SRA expression on DCs in vitro and in vivo. The combination of this complex with the chaperone vaccine promotes a cytotoxic T lymphocyte response and reprograms the tumor environment. The findings suggest the potential for further optimization of the chitosan-siRNA formulation to enhance the immunotherapeutic benefits of chaperone vaccine.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Engineering, Biomedical
Xing Chen, Xiang Ling, Jiaxuan Xia, Ying Zhu, Longlong Zhang, Yuwei He, Anni Wang, Guolong Gu, Bo Yin, Jianxin Wang
Summary: The cytomembrane-derived delivery platform is a promising biomimetic strategy for oncotherapy. By fusing mature dendrosomes with redox-responsive nanoparticles, durable and reliable tumor inhibition can be achieved, along with enhanced immunogenicity and immunocyte differentiation. Combination with aPD-L1 further enhances the antitumor effect.
BIOACTIVE MATERIALS
(2022)
Article
Cell Biology
Vanaja Konduri, Sujith K. Joseph, Tiara T. Byrd, Zeid Nawas, Jonathan Vazquez-Perez, Colby J. Hofferek, Matthew M. Halpert, Dongliang Liu, Zhengdong Liang, Yunyu Baig, Vita S. Salsman, Damilola Oyewole-Said, Anna Tsimelzon, Briana A. Burns, Changyi Chen, Jonathan M. Levitt, Qizhi Yao, Nabil M. Ahmed, Meenakshi Hegde, William K. Decker
Summary: The CD161-expressing T cell subset identified by the NK cell marker CD161 in humans exhibits enhanced cytotoxic and memory phenotypes, making it a potentially effective candidate for chimeric antigen receptor (CAR) T cell therapy. Gene expression profiling in mice shows up-regulation of cytotoxic markers and innate signaling molecules in CD161-expressing CD8(+)NK1.1(+) T cells, leading to improved protection against tumor and viral infections. Furthermore, human CD8(+)CD61(+) T cells demonstrate heightened killing activity and improved efficacy in CAR therapy targeting solid tumors.
SCIENCE TRANSLATIONAL MEDICINE
(2021)
Article
Oncology
Jitske van den Bulk, Manon van der Ploeg, Marieke E. Ijsselsteijn, Dina Ruano, Ruud van der Breggen, Rebekka Duhen, Koen C. M. J. Peeters, Arantza Farina-Sarasqueta, Els M. E. Verdegaal, Sjoerd H. van der Burg, Thomas Duhen, Noel F. C. C. de Miranda
Summary: Expression of CD103 and CD39 can specifically identify neoantigen-specific CD8(+) T cells in colorectal cancers (CRCs) with low mutation burden.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Francesco De Sanctis, Alessia Lamolinara, Federico Boschi, Chiara Musiu, Simone Caligola, Rosalinda Trovato, Alessandra Fiore, Cristina Frusteri, Cristina Anselmi, Ornella Poffe, Tiziana Cestari, Stefania Cane, Silvia Sartoris, Rosalba Giugno, Giulia Del Rosario, Barbara Zappacosta, Francesco Del Pizzo, Matteo Fassan, Erica Dugnani, Lorenzo Piemonti, Emanuela Bottani, Ilaria Decimo, Salvatore Paiella, Roberto Salvia, Rita Teresa Lawlor, Vincenzo Corbo, Youngkyu Park, David A. Tuveson, Claudio Bassi, Aldo Scarpa, Manuela Iezzi, Stefano Ugel, Vincenzo Bronte
Summary: PDAC tumors exhibit strong immunosuppressive characteristics that limit the success of immunotherapy. Research shows that reprogramming the tumor microenvironment by intervening in RNS production can enhance the efficacy of immune-based treatments.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Biochemistry & Molecular Biology
Mingzu Guo, Wenxi Xu, Yoshinari Yamamoto, Takuya Suzuki
Summary: The study found that curcumin can increase the expression of HSP70 in intestinal Caco-2 cells through transcriptional activation, possibly enhancing cell integrity. The effects of curcumin are regulated by various signaling pathways. This discovery is expected to contribute to a deeper understanding of the regulation of intestinal HSP70 by dietary components.
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
(2021)
Article
Oncology
Natalia Plewa, Lucia Poncette, Thomas Blankenstein
Summary: This study suggests that HLA-DR4-restricted TCRs specific for the TGF beta R2(-1) recurrent neoantigen could be valuable candidates for adoptive T cell therapy in cancer patients.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2023)
Article
Oncology
Mirela Kremenovic, Alfred A. Chan, Bing Feng, Lukas Baeriswyl, Steve Robatel, Thomas Gruber, Li Tang, Delphine J. Lee, Mirjam Schenk
Summary: In this study, a novel BCG lysate was developed and formulated into a thermosensitive hydrogel. The BCG lysate exhibited enhanced antitumor efficacy and promoted a proinflammatory tumor microenvironment in vivo. The underlying mechanisms of BCG lysate-mediated tumor immunity relied on macrophages (M phi) and dendritic cells (DCs). The BCG hydrogel treatment induced systemic immunity, suppressed lung metastases, and improved survival in melanoma-bearing mice. Furthermore, BCG hydrogel treatment enhanced antigen processing and presentation, and increased the frequency of melanoma-reactive CD8(+) T cells. In human melanoma patients, intralesional-BCG treatment was associated with enhanced M1 M phi, mature DCs, antigen processing and presentation, and increased patient survival.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
Article
Oncology
Malgorzata Bajor, Agnieszka Graczyk-Jarzynka, Katsiaryna Marhelava, Anna Burdzinska, Angelika Muchowicz, Agnieszka Goral, Andriy Zhylko, Karolina Soroczynska, Kuba Retecki, Marta Krawczyk, Marta Klopotowska, Zofia Pilch, Leszek Paczek, Karl-Johan Malmberg, Sebastien Walchli, Magdalena Winiarska, Radoslaw Zagozdzon
Summary: This study provides new information on the efficacy of PD-L1-targeted CAR against PD-L1(low) targets. The results show that PD-L1-CAR cells have strong reactivity and cytotoxicity against both PD-L1(high) and PD-L1(low) target cells. Additionally, PD-L1-CAR cells also exhibit potent cytotoxic effects against non-malignant cells.
JOURNAL FOR IMMUNOTHERAPY OF CANCER
(2022)
